FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome
Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia With Multilineage Dysplasia
Acute Undifferentiated Leukemia
Recurrent Follicular Lymphoma
T Lymphoblastic Lymphoma
Acute Erythroid Leukemia in Remission
Acute Myeloid Leukemia With FLT3/ITD Mutation
Ph+ ALL
Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-12-09

Last Posted Date: 2023-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 46

Registration Number: NCT01028716

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Conditions: Melanoma (Skin)

First Posted Date: 2009-11-01

Last Posted Date: 2010-08-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01005537

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Rituximab
Drug: Vorinostat

First Posted Date: 2009-10-09

Last Posted Date: 2020-03-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00992446

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia
Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts
Secondary Acute Myeloid Leukemia

Interventions: Biological: Pretargeted Radioimmunotherapy
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-10-02

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00988715

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis

First Posted Date: 2009-08-31

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00968630

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Sulforaphane on Normal Prostate Tissue

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: High Sulforaphane Extract (Broccoli Sprout Extract)
Drug: Microcrystalline Cellulose NF (placebo)

First Posted Date: 2009-07-27

Last Posted Date: 2016-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00946309

Locations: 🇺🇸
VA Puget Sound, Seattle, Washington, United States

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma
Stage III Melanoma
Recurrent Melanoma

Interventions: Biological: therapeutic autologous lymphocytes
Biological: aldesleukin
Biological: denileukin diftitox
Procedure: biopsy
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction

First Posted Date: 2009-07-24

Last Posted Date: 2022-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00945269

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Phase 3

Completed

Conditions: Graft Versus Host Disease
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: methylprednisolone
Other: questionnaire administration

First Posted Date: 2009-06-29

Last Posted Date: 2017-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 164

Registration Number: NCT00929695

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant

Completed

Conditions: Cardiovascular Complications
Leukemia
Long-term Effects Secondary to Cancer Therapy in Children
Metabolic Syndrome

First Posted Date: 2009-06-15

Last Posted Date: 2012-12-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 244

Registration Number: NCT00920842

Locations: 🇺🇸
Clinical Research Center - Seattle Children's Hospital, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy